Navigation Links
Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting
Date:6/1/2009

test information regarding ongoing carfilzomib clinical trials, please visit www.clinicaltrials.gov.

About Proteolix

Founded in December 2003, Proteolix, Inc. is a privately-held biotechnology company, headquartered in South San Francisco, dedicated to discovering, developing and commercializing novel therapeutics that target protein degradation pathways for cancer and autoimmune diseases. Proteolix's lead product, carfilzomib, is the first in a new class of selective, irreversible proteasome inhibitors. Proteolix is also developing a pipeline of novel proteasome inhibitors, including a selective, oral proteasome inhibitor and a selective immunoproteasome inhibitor. For additional information on Proteolix, please visit www.proteolix.com.

    Contact information
    Media Inquiries:                        All Other Inquiries:
    BCC Partners                            Craig C. Parker
    Karen L. Bergman or Michelle Corral     Senior Vice President,
                                             Finance and Corporate
    650-575-1509 or 415-794-8662            Development & Chief Financial
                                             Officer
                                            650-266-2825


'/>"/>
SOURCE Proteolix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
2. Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology
3. Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
4. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
5. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
8. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
9. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
10. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting
11. MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , January 23, 2015 Heptares Therapeutics, the ... to announce that the Malcolm Campbell Memorial Prize ... (Vice President of Chemistry), Fiona Marshall (Chief Scientific ... Officer and co-founder) for the seminal contributions to GPCR drug ...
(Date:1/22/2015)... DIEGO, Jan. 22, 2015  ResMed Inc. (NYSE: RMD ... 2014. Revenue for the quarter was $423.0 million, a 10 ... (a 14 percent increase on a constant currency basis). Net ... to the quarter ended December 31, 2013. Diluted earnings per ...
(Date:1/22/2015)... Calif. , Jan. 22, 2015 Increasing sophistication ... continued consolidation of localization purchasing in 2015, says ... According to a recent study by market research firm ... a single-source solution for their translation and localization needs. ...
Breaking Medicine Technology:Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2
... NEW YORK, Nov. 3, 2011 Intellect Neurosciences, ... the discovery and development of disease-modifying therapeutic agents ... diseases announced today that it has filed a ... its antibody methods application Serial  No. 10/084,380, one ...
... 2011 Savient Pharmaceuticals, Inc. (NASDAQ: SVNT ) ... ended September 30, 2011, which reflect the Company,s continuing investment ... quarter with $202.7 million in cash and short-term investments, a ... quarter of 2011, the Company had a net loss of ...
Cached Medicine Technology:Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN® Alzheimer's Patent Application 2Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN® Alzheimer's Patent Application 3Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results 2Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results 3Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results 4Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results 5Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results 6Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results 7
(Date:1/22/2015)... California (PRWEB) January 22, 2015 The City of ... at 10 a.m., to commemorate the 42nd anniversary of the Supreme ... States. , “It’s been 42 years since the Roe vs. Wade ... is still as present as ever,” said City of West Hollywood ...
(Date:1/22/2015)... is a seasoned and trusted leader who consistently delivers trendy ... have it lead the wedding dress industry into the future. ... for the global market. , “The CEO of VogueQueen is ... on continuing the goal of operational excellence and giving back ...
(Date:1/22/2015)... 23, 2015 AngelWeddingDress, the premier women’s ... maternity wedding dresses. View website of AngelWeddingDress.com ... for maternity wedding dresses online for a bridal party. ... high quality for them. Its maternity wedding dresses are ...
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 ... after Fresenius Medical Care recalled its GranuFlo and NaturaLyte ... multidistrict litigation underway in U.S. District Court, District of ... dated January 20th, the Court has remanded a case ...
(Date:1/22/2015)... January 22, 2015 Joan Lunden, award-winning ... speaker at the upcoming 32nd Annual Miami Breast ... Physicians’ Education Resource®, LLC (PER®) , shares that “a ... gone undetected if she had not followed up her ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6
... Scientific Pioneers Invest in Evolving Field of Protein ... Millennium,Pharmaceuticals, Inc. (Nasdaq: MLNM ) and Harvard ... innovative collaboration,agreement to pursue a research program in ... field of cancer biology. Under the terms of ...
... throughout Minnesota, MINNEAPOLIS, Jan. 31 A ... 76 percent of Minnesotans support the,statewide smoke-free law, ... provides evidence of strong support among all leading,demographics, ... gender. The survey was conducted by Minneapolis research,firm ...
... - New Information Strengthens Community,s Demand to Save St. ... ... Sutter Health told the San,Francisco Chronicle in a January 27 article the ... St. Luke,s,Hospital, the South of Market facility they are trying to close:, ...
... The Company,s first acne product enters the ... Jan. 30 Skinvisible, Inc. (OTC,Bulletin Board: ... company focused on formulating and enhancing patented,dermatology ... announced it has signed an exclusive licensing ...
... Survey of User Satisfaction puts IDC on top ... /PRNewswire-FirstCall/ - IDC (Imaging Dynamics,Company, Ltd.) (TSX: IDL), ... today announced that for the third consecutive,quarter it ... digital,detector radiography systems among 11 vendors in the ...
... N.Y., Jan. 30 Moog Inc. (NYSE:,MOG.A and MOG.B) ... John,Scannell, CFO, will present at the 29th Annual Cowen ... 2008 at 11:10 a.m. EST., Listeners can access ... . Please allow 15 minutes prior,to the call to ...
Cached Medicine News:Health News:Millennium and Harvard Medical School Sign Cooperative Agreement for Research in Novel Field of Cancer Biology 2Health News:Millennium and Harvard Medical School Sign Cooperative Agreement for Research in Novel Field of Cancer Biology 3Health News:Millennium and Harvard Medical School Sign Cooperative Agreement for Research in Novel Field of Cancer Biology 4Health News:Millennium and Harvard Medical School Sign Cooperative Agreement for Research in Novel Field of Cancer Biology 5Health News:Millennium and Harvard Medical School Sign Cooperative Agreement for Research in Novel Field of Cancer Biology 6Health News:New Survey Finds 76 Percent of Minnesotans Support Smoke-Free Law 2Health News:Skinvisible Announces Licensing Agreement for Adapalene 2Health News:Skinvisible Announces Licensing Agreement for Adapalene 3Health News:IDC Digital radiography systems Ranked #1 for third consecutive quarter 2
... offer a wide range of storage capacities. ... storage platform to agitate smoothly, eliminating the ... and squeak. Sturdy, one-piece perforated drawers with ... for your platelets., ,i.Series platelet agitators feature ...
Platelet agitator....
Reciprocating shaker specifically for platelet bags....
... the quantitative determination of ... serum. Progesterone EIA ... principle of competitive binding ... test specimen and progesterone-HRP ...
Medicine Products: